Second Read and Referred S Judiciary and Civil and Criminal Jurisprudence Committee
Email me when SB 1724 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track SB 1724. By continuing you agree to the Terms and Privacy Policy.
Summary
The bill repeals the current Section 195.017 and rewrites it to add xylazine as a Schedule III drug, limiting its possession and distribution to specific veterinary, research, and pharmaceutical exemptions. It would subject any xylazine‑containing product to the same controls as other Schedule III substances, affecting veterinarians, pharmacists, manufacturers, and anyone handling the drug. The measure failed after a second reading and referral to the Senate Judiciary and Civil and Criminal Jurisprudence Committee.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about SB 1724
3 free questions a day, no accountHistory
- Second Read and Referred S Judiciary and Civil and Criminal Jurisprudence Committee
- S First Read
Sponsors
- Justin Brown (R) · sponsor
- Brown (16), Justin
Similar bills in other states
Loading the map of where bills like this one were filed.
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when SB 1724 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track SB 1724 freeOr ask your AI assistant about SB 1724 directly:
Add to Claude, ChatGPT or Cursor